Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.70 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.67 |
| ▸ | GAK | O14976 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 2/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.67 |
| ▸ | MET | P08581 | 2/20 | 0.67 |
| ▸ | PHKG2 | P15735 | 2/20 | 0.67 |
| ▸ | BLK | P51451 | 2/20 | 0.67 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.67 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.67 |
| ▸ | EPHA6 | Q9UF33 | 2/20 | 0.67 |
| ▸ | CIT | O14578 | 1/20 | 0.67 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.67 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.67 |
| ▸ | STK10 | O94804 | 1/20 | 0.67 |
| ▸ | LYN | P07948 | 1/20 | 0.67 |
| ▸ | RET | P07949 | 1/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1418193 | 1.00 | EGFR (0.70) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL3577825 | 0.94 | EGFR (0.73) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL3577826 | 0.94 | EGFR (0.73) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL1191397 | 0.93 | EGFR (0.71) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL1191345 | 0.92 | EGFR (0.67) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL1191791 | 0.92 | EGFR (0.67) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL1192059 | 0.92 | EGFR (0.67) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL1191789 | 0.92 | EGFR (0.67) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL1191347 | 0.92 | EGFR (0.67) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL1191344 | 0.92 | EGFR (0.67) | EGFRERBB2ERBB4GAKABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020077330-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-20 | — | — | US | claimed |
| EP-2298746-A1 | 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-6972288-B1 | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-12-06 | — | — | US | disclosed |
| US-6653305-B2 | For therapy of tumoral diseases, diseases of the lungs and respiratory tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-11-25 | — | — | US | disclosed |
| US-20020077330-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077330-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NR3C2, CYP11B2 | EGFR 417/4885ERBB2 545/4885ERBB4 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.